COVID-19 diagnosis and management: a comprehensive review

Journal of Internal Medicine

Volumn 288, Issue 2, 2020, Pages 192-206

  Pascarella, Giuseppe ^a   Strumia, Alessandro ^a   Piliego, Chiara ^a   Bruno, Federica ^a   Del Buono, Romualdo ^b   Costa, Fabio ^a   Scarlata, Simone ^a   Agrò, Felice Eugenio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Humanitas Mater Domini Hospital   (Italy)

Author keywords

COVID 19; COVID 19 diagnosis; COVID 19 management; COVID 19 treatment; novel coronavirus; SARS CoV 2

Indexed keywords

ANTIVIRUS AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; IMMUNOSTIMULATING AGENT; MONOCLONAL ANTIBODY;

CELL THERAPY; CLINICAL FEATURE; CORONAVIRUS DISEASE 2019; DIAGNOSTIC TEST; DISEASE COURSE; HUMAN; LABORATORY TEST; MESENCHYMAL STROMA CELL; META ANALYSIS; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY CARE; RESPIRATORY DISTRESS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW; VIRUS TRANSMISSION; X-RAY COMPUTED TOMOGRAPHY; BETACORONAVIRUS; CORONAVIRUS INFECTION; DIAGNOSTIC IMAGING; LABORATORY TECHNIQUE; LUNG; PANDEMIC; PATIENT ISOLATION; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CLINICAL LABORATORY TECHNIQUES; CORONAVIRUS INFECTIONS; HUMANS; HYDROXYCHLOROQUINE; LUNG; PANDEMICS; PATIENT ISOLATION; PNEUMONIA, VIRAL; RESPIRATORY THERAPY;

EID: 85084440197     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.13091     Document Type: Review

References (127)

1. Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? The Lancet 2020; 395: 1225–8.
2. Holshue ML, DeBolt C, Lindquist S et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 2020; 382: 929–36.
3. Bernard Stoecklin S, Rolland P, Silue Y et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Eurosurveillance 2020; 25: 2000094.
4. Liu J, Zheng X, Tong Q et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020; 92: 491–4.
5. Mahase E. Covid-19: WHO declares pandemic because of “alarming levels” of spread, severity, and inaction. BMJ 2020; 368: m1036.
6. WHO. Novel coronavirus situation dashboard. Geneva, Switzerland: WHO, 2020
7. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: what we know. Int J Infect Dis 2020; 94: 44–8.
8. Liu K, Chen Y, Lin R, Han K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infection 2020. [Epub ahead of print].
9. Lake MA. What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond) 2020; 20: 124–7.
10. Adhikari SP, Meng S, Wu YJ et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty 2020; 9: 29.
11. Lauer SA, Grantz KH, Bi Q et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Int Med 2020; 172: 577.
12. Rothe C, Schunk M, Sothmann P et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med 2020; 382: 970–1.
13. Yu P, Zhu J, Zhang Z, Han Y. A Familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis 2020. [Epub ahead of print].
14. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect 2020; 104: 246–51.
15. Lan L, Xu D, Ye G et al. Positive RT-PCR test results in patients recovered from COVID-19. JAMA 2020; 323: 1502.
16. Prevention CfDCa. Discontinuation of Home Isolation for Persons with COVID-19 (Interim Guidance). Atlanta, Georgia: Center for Disease Control and Prevention, 2020.
17. Woelfel R, Corman VM, Guggemos W et al. Clinical presentation and virological assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster. medRxiv 2020.
18. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med 2020. [Epub ahead of print].
19. Peng PWH, Ho P-L, Hota SS. Outbreak of a new coronavirus: what anaesthetists should know. Br J Anaesth; 124: 497–501.
20. Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA 2020; 323: 1061.
21. D'Adamo H, Yoshikawa T, Ouslander JG. Coronavirus Disease 2019 in Geriatrics and Long-term Care: The ABCDs of COVID-19. J Am Geriatr Soc 2020. [Epub ahead of print].
22. Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Can J Anaesth 2020; 67: 568–76.
23. Zhou G, Chi C. A model simulation study on effects of intervention measures in Wuhan COVID-19 epidemic. Medrxiv 2020.
24. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak with the same measures as for SARS? Lancet Infect Dis 2020; 20: e102–107.
25. He F, Deng Y, Li W. Coronavirus disease 2019 (COVID-19): What we know? J Med Virol 2020. [Epub ahead of print].
26. Yang J, Zheng Y, Gou X et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International journal of infectious diseases. IJID 2020; 94: 91–5.
27. Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020; 109: 531–38.
28. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 2020; 395: 507–13.
29. Yang X, Yu Y, Xu J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med 2020; 8: 475–81.
30. Li LQ, Huang T, Wang YQ et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol 2020; 92: 577–83.
31. Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr 2020; 87: 281–6.
32. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol 2020; 92: 548–51.
33. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92: 552–5.
34. Desforges M, Le Coupanec A, Dubeau P et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 2020; 12: 14.
35. Sun T, Guan J. Novel coronavirus and central nervous system. Eur J Neurol 2020. [Epub ahead of print].
36. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020; 323: 1239–42.
37. Xu Z, Shi L, Wang Y et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Resp Med 2020; 8: 420–2.
38. Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky AS. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intens Care Med 2020; 46: 579–82.
39. Bouadma L, Lescure F-X, Lucet J-C, Yazdanpanah Y, Timsit J-F. Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists. Intens Care Med 2020; 46: 579–82.
40. Guan W-j, Ni Z-y, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708–20.
41. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020; 35: 1545–9.
42. Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054–62.
43. Wang W, Xu Y, Gao R et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020. [Epub ahead of print].
44. WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Interim Guid. Geneva, Switzerland: World Health Organization site, 2020.
45. Zou L, Ruan F, Huang M et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177–9.
46. Zhang W, Du R-H, Li B et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microb Infect 2020; 9: 386–9.
47. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. The Lancet 2020; 395: 497–506.
48. Young BE, Ong SWX, Kalimuddin S et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020; 323: 1488.
49. Yong Zhang CC, Zhu Shuangli, Shu Chang et al. Isolation of 2019-nCoV from a stool specimen of a laboratory-confirmed case of the coronavirus disease 2019 (COVID-19). China CDC Weekly 2020; 2: 123–4.
50. Memish ZA, Assiri AM, Al-Tawfiq JA. Middle East respiratory syndrome coronavirus (MERS-CoV) viral shedding in the respiratory tract: an observational analysis with infection control implications. Int J Infect Dis 2014; 29: 307–8.
51. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 101623. [Epub ahead of print].
52. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386: 995–1007.
53. Chan KH, Poon LLLM, Cheng VCC et al. Detection of SARS coronavirus in patients with suspected SARS. Emerg Infect Dis 2004; 10: 294–9.
54. Cheng PK, Wong DA, Tong LK et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. Lancet 2004; 363: 1699–700.
55. Hung IF, Cheng VC, Wu AK et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis 2004; 10: 1550–7.
56. Peiris JS, Chu CM, Cheng VC et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767–72.
57. Liu W, Tang F, Fontanet A et al. Long-term SARS coronavirus excretion from patient cohort. China. Emerg Infect Dis 2004; 10: 1841–3.
58. Corman VM, Albarrak AM, Omrani AS et al. Viral shedding and antibody response in 37 patients with middle east respiratory syndrome coronavirus infection. Clin Infect Dis 2016; 62: 477–83.
59. Ai T, Yang Z, Hou H et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology 2019; 2020: 200642.
60. Zhuang GH, Shen MW, Zeng LX et al. Potential false-positive rate among the 'asymptomatic infected individuals' in close contacts of COVID-19 patients. Zhonghua Liu Xing Bing Xue Za Zhi 2020; 41: 485–8.
61. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020. [Epub ahead of print].
62. Driggin E, Madhavan MV, Bikdeli B et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol 2020; 75: 2352–71.
63. Kanne JP, Little BP, Chung JH, Elicker BM, Ketai LH. Essentials for radiologists on COVID-19: an update—radiology scientific expert panel. Radiology 2020; 200527. [Epub ahead of print].
64. Bernheim A, Mei X, Huang M et al. Chest CT findings in coronavirus disease-19 (COVID- 19): relationship to duration of infection. Radiology 2020; 200463. [Epub ahead of print].
65. Yi Huang S, Liu Y, Zhang Y, Chuyun Zheng Y, Zheng CZ, Min W, Ming Y, Mingjun H. A preliminary study on the ultrasonic manifestations of peripulmonary lesions of non-critical novel coronavirus pneumonia (COVID-19). Research square.
66. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad Ali. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. Am J Roentgenol 2019; 2020: 1–7.
67. Shi H, Han X, Jiang N et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20: 425–34.
68. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38: 1–9.
69. Pang J, Wang MX, Ang IYH et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J Clin Med 2020: 9: 623.
70. Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of novel coronavirus 2019-nCoV: Need for rapid vaccine and biologics development. Pathogens 2020; 9: 148.
71. Brooks SK, Webster RK, Smith LE et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. The Lancet 2020; 395: 912–20.
72. Parmet WE, Sinha MS. Covid-19 — The law and limits of quarantine. N Engl J Med 2020; 382: e28.
73. Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens 2020; 9: 186.
74. Yang Y, Peng F, Wang Ret al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2003; 2020: 102434.
75. Zhang T, He Y, Xu W, Ma A, Yang Y, Xu K-F. Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need. Sci China Life Sci 2020; 63: 774–6.
76. WHO. Coronavirus disease (COVID-19) technical guidance: Patient management. Geneva, Switzerland: WHO, 2020.
77. Prevention CfDCa. Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). Atlanta, Georgia: Center for Disease Control and Prevention, 2020.
78. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet 2020; 395: 473–5.
79. Zhou W, Liu Y, Tian D et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Sign Trans Target Therap 2020; 5: 18.
80. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 9: 727–32.
81. Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020; 101615. [Epub ahead of print].
82. Agostini ML, Andres EL, Sims AC et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018; 9: e00221-18.
83. Sheahan TP, Sims AC, Leist SR et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.
84. Chu CM, Cheng VC, Hung IF et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252–6.
85. Lim J, Jeon S, Shin HY et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020; 35: e79.
86. Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option. J Med Virol 2020; 92: 556–63.
87. Han W, Quan B, Guo Y et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol 2020; 92: 461–3.
88. SIMIT. Vademecum per la cura delle persone con malattia da COVID-19. Prato, Italy: SIMIT, 2020.
89. Cao B, Wang Y, Wen D et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med 2020; 382: 1787–1799.
90. Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect Dis 2006; 6: 67–9.
91. Vincent MJ, Bergeron E, Benjannet S et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69-.
92. Yan Y, Zou Z, Sun Y et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 2013; 23: 300–2.
93. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72–3.
94. The multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Chin J Tuberc Respir Dis 2020; 43: 185–8.
95. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020. [Epub ahead of print].
96. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020; 177: 104762.
97. Gautret P, Lagier J-C, Parola P et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; 105949. [Epub ahead of print].
98. Wang M, Cao R, Zhang L et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269–71.
99. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55: 105932.
100. Yao X, Ye F, Zhang M et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. [Epub ahead of print].
101. Haeusler IL, Chan XHS, Guérin PJ, White NJ. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 2018; 16: 200.
102. Spinelli FR, Ceccarelli F, Di Franco M, Conti F. To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. Ann Rheum Dis 2020; 79: 666–7.
103. Guo YR, Cao QD, Hong ZS et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res 2020; 7: 11.
104. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med 2020; 46: 315–28.
105. Rello J, Tejada S, Userovici C, Arvaniti K, Pugin J, Waterer G. Coronavirus disease 2019 (COVID-19): A critical care perspective beyond China. Anaesth Crit Care Pain Med 2020; 39: 167–9.
106. Fan E, Del Sorbo L, Goligher EC et al. An official American thoracic society/European Society of Intensive Care Medicine/Society of critical care medicine clinical practice guideline: Mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 195: 1253–63.
107. Li T. Diagnosis and clinical management of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union Medical. College Hospital (V2.0). Emerg Microb Infect 2020; 9: 582–5.
108. Munshi L, Del Sorbo L, Adhikari NKJ et al. Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis. Ann Am Thorac Soc 2017; 14: S280–s8.
109. MacLaren G, Fisher D, Brodie D. Preparing for the most critically Ill patients with COVID- 19: the potential role of extracorporeal membrane oxygenation. JAMA 2020; 323: 1245–6.
110. Horie S, Gonzalez HE, Laffey JG, Masterson CH. Cell therapy in acute respiratory distress syndrome. J Thorac Dis 2018; 10: 5607–20.
111. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020; 395: e35–e6.
112. Chakraborty A, Tannenbaum S, Rordorf C et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 2012; 51: e1–18.
113. Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2016; 11: 81–90.
114. Chenoweth AM, Wines BD, Anania JC, Mark Hogarth P. Harnessing the immune system via FcgammaR function in immune therapy: A pathway to next-gen mAbs. Immunol Cell Biol 2020; 98: 287–304.
115. Li W, Moore MJ, Vasilieva N et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450–4.
116. Dimitrov DS. The secret life of ACE2 as a receptor for the SARS virus. Cell 2003; 115: 652–3.
117. Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci USA 2004; 101: 4240.
118. Kuhn JH, Li W, Radoshitzky SR, Choe H, Farzan M. Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies. Antivir Ther 2007; 12: 639–50.
119. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res 2020. [Epub ahead of print].
120. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2007; 74: 92–101.
121. Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem 2004; 12: 2517–21.
122. Sui J, Li W, Murakami A et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004; 101: 2536–41.
123. Khan S, Siddique R, Shereen MA et al. The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options. J Clin Microbiol 2020; 58: e00187-20.
124. van de Veerdonk FNMGN, van Deuren M, van der Meer JW, de Mast Q, Bruggemann RJ, van der Hoeven H. Kinins and cytokines in COVID-19: A comprehensive pathophysiological approach. Preprints 2020.
125. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020; 92: 479–90.
126. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sinica 2020. [Epub ahead of print].
127. Liu L, Wei Q, Lin Q et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 2019; 4: e123158.